E
Enliven Therapeutics, Inc. (ELVN)
NMS – Real Time Price. Currency in USD
50.08
+0.96 (1.95%)
At close: Jun 26, 2026, 4:00 PM EDT
49.73
-0.35 (-0.70%)
After-hours: Jun 26, 2026, 6:31 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
50.08
+0.96 (1.95%)
At close: Jun 26, 2026, 4:00 PM EDT
49.73
-0.35 (-0.70%)
After-hours: Jun 26, 2026, 6:31 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $132.2M significantly exceed its total debt $302.0K, ensuring strong financial flexibility
Total current assets $463.1M exceed Total current liabilities $11.5M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$19.3M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 40.32 | 6.05 | 10 | |
| Quick ratio | 40.32 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -215K | -297K | -317K | -263K | -203K |
| Operating Income | -39M | -84M | -105M | -120M | -116M |
| Net Income | -38M | -72M | -89M | -104M | -99M |
| EBITDA | -39M | -83M | -104M | -119M | -116M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 18.07 | 5.0 |
| Next quarter | N/A | -42.91 | 1.0 |
| Current year | N/A | 3.28 | 2.5 |
| Next year | N/A | -35.73 | 1.0 |
| Weighted average score | 2.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 20.36 | 20.83 | -21.79 | 7.8 |
| Y/Y | 999 | 17.23 | 33.33 | 20.11 | 9.8 |
| 3y average | 999 | -43.62 | 18.17 | -34.43 | 5.3 |
| 5y average | 999 | -28.57 | 29.71 | -24.81 | 5.5 |
| Weighted average score | 7.1 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |